EMA Recommends Extending Indications for Decitabine / Cedazuridine By Ogkologos - May 29, 2026 2 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a combination with venetoclax for the treatment of adult patients with newly diagnosed AML Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline ESMO Shares Recommendations to Support Cancer Research and Clinical Trials in Europe MOST POPULAR What Is Pancreatic Enzyme Replacement Therapy in Cancer Care? June 22, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Tafasitamab July 8, 2021 Grabbing the Perfect Gift December 16, 2023 ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being... September 10, 2024 Load more HOT NEWS Latest Data Indicate New Care Standard in Advanced/Recurrent Endometrial Cancer: Results... Mobile Care Center Brings Breast Cancer Treatment to Amish and Mennonite... FDA Grants Accelerated Approval to Dabrafenib in Combination with Trametinib for... EMA Recommends Extension of Indications for Nivolumab
